2
Clinical Trials associated with TKD activated NK cells (Alphageneron Pharmaceuticals)A phase I study of combination adjuvant immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with resectable hepatocellular carcinoma - A phase I study of combination adjuvant immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with resectable hepatocellular carcinoma
Start Date16 Jan 2018 |
Sponsor / Collaborator- |
A phase I study of combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with advanced or metastatic solid cancer - A phase I study of combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with advanced or metastatic solid cancer
Start Date12 Jan 2016 |
Sponsor / Collaborator- |
100 Clinical Results associated with TKD activated NK cells (Alphageneron Pharmaceuticals)
100 Translational Medicine associated with TKD activated NK cells (Alphageneron Pharmaceuticals)
100 Patents (Medical) associated with TKD activated NK cells (Alphageneron Pharmaceuticals)
100 Deals associated with TKD activated NK cells (Alphageneron Pharmaceuticals)